IBD (Crohn's/ulcerative colitis) conference adds 18 speakers; APS meeting starts Thursday

09/08/04

Final list of topics, including new IBD therapeutic strategies

Snowmass, CO (Sept. 9, 2004) – Based on the quality of the volunteered abstracts submitted for presentation, organizers of the American Physiological Society (APS) conference on Inflammatory Bowel Diseases (IBD) have added 18 speakers to the program Sept. 9-11.

The IBD conference, which kicks off in Snowmass, Colorado Sept. 8 with a keynote address by Dr. Daniel Podolsky of the Massachusetts General Hospital, comprehensively deals with diseases that are for the most incurable and whose causes are still unknown.

One of the co-organizers, Matthew B. Grisham, professor in the Department of Molecular and Cell Physiology at Louisiana State University Health Science Center, said about half the 18 additional speakers are comparatively young up-and-coming researchers, "and for most of them, this probably will be their first oral presentation at a major conference."

Broad range of topics reflects comprehensive attack on IBD

Three speakers have been added to each of the six symposia on topics ranging from "new therapeutic strategies in the treatment of IBD" to the "role of the immune system in IBD." (See complete schedule, below.)

Grisham said that the overall quality of the abstracts reflects the fact that IBD is getting the kind of research attention it deserves and needs. "Over the past 15 years, IBD has gone from a somewhat invisible, almost orphan disease to one where almost everyone you talk with knows someone" with either Crohn's Disease or ulcerative colitis, the two constituent diseases of IBD, Grisham added.

Formerly thought of as predominantly a white American and European disease, Grisham said that in those same 15 years or so, the incidence of IBD in Japan, for instance, has risen from a relatively low level to about the same rate as in the U.S. According to the Crohn's and Colitis Foundation of America (CCFA), there are an estimated 1 million IBD sufferers in the U.S., about equally split between male and female, with about 30,000 new diagnoses a year.

CCFA noted that a large HMO tracked IBD-related hospitalizations over six years and reported exactly the same rates for whites and blacks, 10.2 per 100,000 admissions. The hospitalization rates for Hispanics and Asians were lower at the HMO.

Grisham said APS especially wants to thank the other conference sponsors for supporting APS in mounting the timely and comprehensive conference on IBD. Generous support came from Centocor Inc., Hoffman-La Roche Inc., the National Institutes of Health-NIDDK, and CCFA. CCFA also provided much-appreciated background information and statistics on IBD, which can be found at www.ccfa.org.

Editor's note: Telephone or in-person media interviews can be arranged with any of the speakers through APS headquarters by contacting Mayer Resnick at 301-634-7209 (office), 301-332-4402 (cell) or mresnick@the-aps.org both during or after the conference.

Below is the complete list of presentations at the APS conference.

GENETICS OF IBD

  • Mouse Genetics and IBD. Edward Leiter. The Jackson Laboratory.

  • NOD2 Gene Mutations and Crohn's Disease. Judy Cho. University of Chicago.

  • IBD5 and Predisposition to IBD. John Rioux. MIT.

  • Regulation of IL-8 and IL-1beta Expression with Crohn's Disease Associated NOD2/CARD15 Mutations. Jing Li, T. Moran, E. Swanson, C. Julian, I. Wyka, J. Harris, D. Bonen, M. Hedl, D. Nicolae, C. Abraham and J. Cho. Univ. of Chicago.

  • Genetic Variants of NOD2 & Stat6 in Crohn's Disease. Eva Galka, J. Thompson, W.J. Zhang, L. Poritz and W. Koltun. Penn. State University, Milton S. Hershey Medical Center..

  • Growth Hormone Reduces STAT3 Activation and Modulates Cellular Apoptosis and Proliferation in Murine Colitis. Xiaonan Han, E. Bonkowski and L. Denson. Cincinnati Childrens Hosital. Medical Center.

    ROLE OF THE IMMUNE SYSTEM IN INTESTINAL INFLAMMATION: WHO ARE THE PLAYERS AND WHAT DO THEY DO?

  • T Cells Instruct Epithelial Innate Immune Responses via TNF-Induced WNT/BETA Catenin Signaling. Terry Barrett. Northwestern University.

  • Do B Cells Play a Role in IBD? Atul Bhan. Massachusetts General Hospital.

  • Mucosal Antigen Presentation and Tolorance. Cathryn Nagler-Anderson. Mass. Gen. Hosp.

  • L-selectin, ?4?1 and ?4?7 Integrins Participate in CD4+T Cell Recruitment to Chronically Inflamed Small Intestine. Jesus Rivera-Nieves. University of Virginia Health Science Center.

  • Ectopic CD40 Ligand on B Cells Triggers Intestinal Inflammation. Takanori Kanai, T. Kawamura, T. Dohi, T. Totsuka, R. Iiyama, M. Yamazaki, T. Tsubata and M. Watanabe. Tokyo Medical and Dental University and International Medical Center of Japan, Tokyo.

  • Novel Compensatory Vasodilation Mechanism in Microvessels from Patients with Chronic Inflammatory Bowel Disease. Ossama Hatoum, D. Binion, K. Gauthier, H. Miura, G. Telford, M. Otterson, W. Campbell and D. Gutterman. Medical College of Wisconsin.

    INNATE IMMUNE RESPONSES IN INFLAMMATORY BOWEL DISEASE: ROLE OF THE VASCULATURE

  • Leukocyte, Platelet and Endothelial Cell Interactions in Intestinal Inflammation. D. Neil Granger. LSU Health Science Center.

  • Reciprocal Control of CD8 T Cell Homing by Dendritic Cells. J. Rodrigo Mora The CBR Institute for Biomedical Research, Harvard Medical School.

  • Regulation of Epithelial Barrier: Implications in the Pathogenesis of IBD. Asma Nusrat. Emory University.

  • LFA-1 Deficient T-Cells Fail to Induce Chronic Colitis in a T-Cell Dependent Model of Crohn's Disease. Kevin Pavlick, D. Ostanin, F. Laroux, L. Gray, J. Chidlow, Jr., S. Bharwani, C. Kevil and M. Grisham. LSU Hlth. Sci. Ctr.

  • Neoangiogenesis: A New Component in Inflammatory Bowel Disease Pathogenesis. Silvio Danese, M. Sans, C. de la Motte, R. Pola, B. Reyes-Rivera, G. West, H. Phillips, J. Willis, A. Gasbarrini, C. Fiocchi. Case Western Reserve University School of Medicine, The Cleveland Clinic Foundaton., and Universita Cattolica del S. Cuore,Rome, Italy.

  • Gaseous Monoxides in Dextran Sulfate Sodium-Induced Colitis in Mice. Yuji Naito, T. Takagi, K. Katada, H. Tsuboi, N. Yoshida, T. Okanoue and T. Yoshikawa. Kyoto Prefectural University of Medicine.

    CYTOKINES, CHEMOKINES & MEDIATORS OF CHRONIC INFLAMMATION

  • Regulation of Cytokines Expression in Experimental IBD. Theresa Pizarro. University of Virginia Health Science Center.

  • Effector Pathways of TTNF in Models of IBD. Giorgos Kollias. Alexander Flemming Biomedical Science Research Center, Vari, Greece.

  • Th2 Cytokines and Chronic Intestinal Inflammation. Stephen Collins. McMaster University Medical Center.

  • Altered Intestinal Cytokine and Eicosanoid Synthesis in the Gia2-Deficient Mouse Model of Inflammatory Bowel Disease. Robert Edwards, A. Smock and A. Bamberg. University of California, Irvine.

  • Small Intestinal Barrier Dysfunction Precedes Inflammation in the S AMP1/YitFc Model of Spontaneous Crohn's-Like Ileitis. Kevin Scott. University of Virginia.

  • The Protective Effect of Group IIA Secretory Phospholipase A2 in Murine Dss-Induced Colitis is Cox-2 Dependent. Willem de Villiers, J. Zhong, M. Nasser, M. Bostrom, C. Loftin and N. Webb. University of Kentucky Medical Center.

    BACTERIAL/HOST INTERACTIONS IN THE PATHOGENESIS OF IBD

  • Lymphocyte-Bacterial Interactions in Experimental Colitis. Charles Elson Univ. of Alabama at Birmingham.

  • Bacterial-Host Interactions in the mdr1a-/- Model of Intestinal Inflammation. Robin Lorenz. Univ. of Alabama at Birmingham.

  • Crohn's Disease-Associated Bacteria: Lessons from P. fluorescens pfiT (I2 protein). Jonathan Braun. UCLA School of Medicine.

  • Expression and Functional Relevance of Intestinal Epithelial Bactericidal Permeability-Increasing Protein. Geraldine Canny, A. Lennartsson, O. Levy, U. Gullberg and S. Colgan. Brigham and Women's Hospital, Lund University and Children's Hospital.

  • GM-CSF and Host Cytokine Response in Murine Inflammatory Models. Brian Dieckgraefe, J. Korzenik, S. Anant, Q. Gong, M. Gilbert and D. Hausman. Washington University School of Medicine.

  • Helicobacter Infection to Elucidate the Role of MHC Class II and Dendritic Cells in Inflammatory Bowel Disease in CD11c Transgenic/MHCII/Rag2 Deficient (CD11cTgRII) Mice. Lillian Maggio-Price, H. Bielefeldt-Ohmann, W. Zeng, C. Ware and R. Hershberg., University of Washington and Dendreon Corp., Seattle.

    NEW THERAPEUTIC STRATEGIES IN THE TREATMENT OF IBD

  • Anti-Cytokine Therapy in the Treatment of IBD. Stephan Targan. Cedars-Sinai Medical Center.

  • Anti-Adhesion Therapy in the Treatment of IBD. Julián Panés. Hospital Clínic Barcelona.

  • Probiotic Treatment for Chronic Intestinal Inflammation. Paulo Giochetti. University of Bologna.

  • Platelet Recruitment in Intestinal Inflammation is Modulated by IC AM-1, P-Selectin and PSGL-1. Thorsten Vowinkel, M. Mori, K. Wood, J. Russell, C. Krieglstein and D.N. Granger. LSU Health Science Center, Shreveport and University of Muenster.

  • CTLA-4-Ig Abrogates TNBS Colitis. Gregory Gurtner, T. Ogel, S. Schloemann, K. McDonald, R. Newberry and W. Stenson. Washington University School of Medicine.

  • Intestinal Lactobacillus reuteri-Based Combination Therapy Directly Modulates Mucosal Pro-Inflammatory Cytokine Production in IL-10-Deficient Mice. James Versalovic, J. Pena, A. Rogers, Z. Ge and J. Fox. Baylor College of Medicine, Texas Children's Hospital and MIT.

    Source: Eurekalert & others

    Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
        Published on PsychCentral.com. All rights reserved.

     

     

    A wise man will make more opportunities than he finds.
    -- Sir Francis Bacon
  •  
    Stumble This Article Print Email
    Subscribe to Our Weekly Newsletter

    Users Online: 11102
    Join Us Now!



     




    Find a Therapist
    Enter ZIP or postal code